Tampa, FL USA

Our News on Newswise
View All >

Moffitt Study Links Methylmalonic Acid to Weakening of Immune Cells in Lung Cancer

A new study has found a surprising link between high levels of methylmalonic acid and the weakening of CD8+ T cells, shedding light on potential pathways through which aging may promote lung cancer progression. Moffitt Cancer Center researchers have...
31-Oct-2024 2:05 PM EDT Add to Favorites

Moffitt Study Reveals Insights Into Oral HPV Incidence and Risks in Men Across 3 Countries

A new study has unveiled crucial information about the incidence and risk factors of oral human papillomavirus (HPV) infections among men in the United States, Mexico and Brazil. Moffitt Cancer Center researchers have discovered how often new oral...
21-Oct-2024 9:05 AM EDT Add to Favorites

Moffitt Study Unveils the Role of Gamma-Delta T Cells in Cancer Immunology

TAMPA, Fla. - A new study published in Cell Press reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic targets in cancer treatment. Led by a...
4-Oct-2024 12:00 PM EDT Add to Favorites

Moffitt Researchers Reveal Key LAG3 Mechanisms That Could Transform Cancer Immunotherapy

Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this process is Lymphocyte Activation Gene-3 (LAG3), which suppresses the antitumor...
4-Sep-2024 11:00 AM EDT Add to Favorites

Moffitt Researchers Develop New Chemical Method to Enhance Drug Discovery

Moffitt Cancer Center researchers have developed a novel reagent that enhances the precision of drug synthesis. This innovative method, published in Nature Communications, introduces a new sulfur fluoride exchange (SuFEx) reagent that allows for...
16-Aug-2024 10:05 AM EDT Add to Favorites

Moffitt Consortium Study Answers Questions About Long-Term Survivorship Following CAR T Treatment

Axicabtagene ciloleucel, commonly known as axi-cel, is an innovative immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene...
5-Aug-2024 8:05 AM EDT Add to Favorites

New Moffitt Study Explores How Antifragility Could Revolutionize Cancer Treatment

In a new study published in npj Complexity, Moffitt Cancer Center researchers offer a new perspective on antifragility, proposing a unified framework for understanding the property across different complex systems.
1-Aug-2024 9:05 AM EDT Add to Favorites

Moffitt Study Uncovers Key Immune Cells for Combating Aggressive Merkel Cell Carcinoma

A new study published today in Cancer Discovery is providing insights into why some Merkel cell carcinoma patients respond to this type of immunotherapy while others do not.
26-Jul-2024 9:05 AM EDT Add to Favorites


See All News

Our Experts on Newswise

CANCER AND COVID-19: Moffitt Cancer Center Experts & Resources

1-Apr-2020 8:40 AM EDT

Newswise: AnnaGiuliano_Euroginopeningtalk_2017.jpg

Moffitt Cancer Center HPV Expert Kicked Off EUROGIN Conference

Anna Giuliano, Ph.D., director of Moffitt Cancer Center’s Center for Infection Research in Cancer, delivered the opening keynote address at the 2017 European Research Organization on Genital Infection and Neoplasia (EUROGIN) International...
10-Oct-2017 10:05 AM EDT

See All Experts

Our YouTube Videos
View All >

About

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 56 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 8,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.

Instagram

Facebook

close
0.28535